21 U.S.C. § 360bbb–8c
Patient participation in medical product discussion
Exact citation match for 21 USC § 360BBB-8C
Search
Search by citation or keyword across the current edition within Title 21.
Patient participation in medical product discussion
Exact citation match for 21 USC § 360BBB-8C
Expanded access to unapproved therapies and diagnostics
Expanded access to unapproved therapies and diagnostics
Expanded access policy required for investigational drugs
Expanded access policy required for investigational drugs
Investigational drugs for use by eligible patients
Investigational drugs for use by eligible patients
Authorization for medical products for use in emergencies
Authorization for medical products for use in emergencies
Expedited development and review of medical products for emergency uses
Expedited development and review of medical products for emergency uses
Countermeasure development, review, and technical assistance
Countermeasure development, review, and technical assistance
Priority review to encourage treatments for agents that present national security threats
Priority review to encourage treatments for agents that present national security threats
Critical Path Public-Private Partnerships
Critical Path Public-Private Partnerships
Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments
Consultation with external experts on rare diseases, targeted therapies, and genetic targeting of treatments